Skip to content
Thursday 13 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,802.53
-0.28%
DAX
26,434.24
+0.39%
CAC 40
8,684.00
+0.10%
STOXX 50
6,561.81
+0.43%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Wednesday 29 July 2026 11:30 am

Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

By: Business Wire

Add as a preferred source on Google

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the second quarter and first half ended June 30, 2026, on August 5, 2026.

Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on August 5, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/246696001. The webcast will be archived for 30 days.

About Compass Pathways

We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.

Compass is headquartered in London, UK, with a U.S. office in New Jersey.

We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260729032372/en/

Contact

Enquiries

Media: Dana Sultan-Rothman, [email protected]

Investors: Stephen Schultz, [email protected], +1 401 290 7324

Company Logo
Company Logo
Read more

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Advisory
  • Conference Call
  • Earnings
  • Webcast

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • It’s not just Jason Arday, most of sociology is a scam

  • IT consultant ordered to pay £50,000 after being accused of stealing Soho House members’ personal details

  • Revolut takes flight with launch of new airport lounges

  • As it happened: FTSE 100 falls as Iran and US clash over Strait of Hormuz; Oil stockpiles ‘rapidly depleting’

More from Morning Wire

  • Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

    Business Wire
  • Alkermes plc Reports Second Quarter 2026 Financial Results

    Business Wire
  • Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

    Business Wire
  • IFF to Release Second Quarter 2026 Results on August 4, 2026

    Business Wire
  • IGI to Release Second Quarter and Half Year 2026 Financial Results on August 4, 2026

    Business Wire
  • Luxfer Announces Date of Second Quarter 2026 Earnings Conference Call

    Business Wire
  • Alkermes to Report Second Quarter Financial Results on July 28, 2026

    Business Wire
  • Prothena to Report Second Quarter 2026 Financial Results on August 6

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook